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Background: Cannabinoid receptor 2 (CB2) is expressed predominantly in the immune system, particularly in
plasma cells, raising the possibility that targeting the CB2 pathway could yield an immunomodulatory effect.
Although the role of CB2 in mediating immunoglobulin class switching has been reported, the effects of targeting
the CB2 pathway on immunoglobulin secretion per se remain unclear.
Methods: Human B cell line SKW 6.4, which is capable of differentiating into IgM-secreting cells once treated with
human IL-6, was employed as the cell model. SKW 6.4 cells were incubated for 4 days with CB2 ligands plus IL-6
(100 U/ml). The amount of secreted IgM was determined by an ELISA. Cell proliferation was determined by the
3H-Thymidine incorporation assay. Signal molecules involved in the modulation of IgM secretion were examined by
real-time RT-PCR and Western blot analyses or by using their specific inhibitors.
Results: We demonstrated that CB2 inverse agonists SR144528 and AM630, but not CB2 agonist HU308 or CB1
antagonist SR141716, effectively inhibited IL-6-induced secretion of soluble IgM without affecting cell proliferation
as measured by thymidine uptake. SR144528 alone had no effects on the basal levels of IgM in the resting cells.
These effects were receptor mediated, as pretreatment with CB2 agonist abrogated SR144528-mediated inhibition
of IL-6 stimulated IgM secretion. Transcription factors relevant to B cell differentiation, Bcl-6 and PAX5, as well as the
protein kinase STAT3 pathway were involved in the inhibition of IL-6-induced IgM by SR144528.
Conclusions: These results uncover a novel function of CB2 antagonists and suggest that CB2 ligands may be
potential modulators of immunoglobulin secretion.
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The cannabinoid 1 (CB1) receptor is expressed mainly
in the central nervous system and mediates cannabinoid
neurobehavioral effects, whereas the CB2 receptor is
predominantly expressed in many types of immune cells,
such as B and T lymphocytes and monocytes. The CB2
receptor is thought to be the mediator of cannabinoid-
induced immunomodulatory effects [1-3]. Due to the
distinct expression patterns of CB1 and CB2 in the brain
versus immune system, public concerns that compounds* Correspondence: xix15@pitt.edu
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unless otherwise stated.with high affinity binding to the CB1 subtype may illicit
severe psychotropic side effects has overclouded the
clinical development [4]. Consequently, research and de-
velopment of compounds with high CB2 selectivity, pre-
dictably with no or diminished psychotropic effects, have
garnered much attention particularly in immunomodula-
tion, inflammation, cancer and bone disease prevention
and their treatment [5-12].
The mechanisms by which cannabinoid receptors
modulate immune function have not been fully elu-
cidated. As an inhibitory Gi/o protein-coupled receptor,
CB2 activation is associated with the inhibition of cyclic
AMP formation, which results from Gi protein-induced
inhibition of adenylyl cyclase. Conversely, CB2 antagon-
ist SR144528 alone can stimulate the forskolin-sensitived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ition of forskolin-stimulated cAMP [13]. Although the
CB1 pathway may also be involved in immunoregulation
[14], CB2 has been shown to be the cannabinoid re-
ceptor primarily responsible for the anti-inflammatory
and possible immune therapeutic effects of cannabis
[8,15]. Among the various immune mechanisms influ-
enced by cannabinoids, T helper (Th) cell biasing has
been reported with suppression of Th1 (e.g. decrease
in IgG2a) and enhancement of Th2 immunity (e.g. in-
crease of serum IgE or IgG1) [8]. Previous studies
have shown that delta-9-tetrahydrocannabinol inhibits
the mouse plaque-forming cell assay for antibody for-
mation [7]. Furthermore, CB2 mediates immunoglobulin
class switching from IgM to IgE in cultures of murine B
lymphocytes [16].
A consideration in the study of CB2 and immune
function is the model species used. While mouse is the
primary animal model for biological studies, one should
be cautious to extrapolate human effects from animal
data when investigating pharmacological and immuno-
logical responses of CB2 ligands in diverse species [15].
Unlike for CB1, there is a considerable level of sequence
variation and gene expression difference for CB2 among
human, mouse and rat species. Of note, it is the C-
terminus of CB2 that plays a critical role in regulating
receptor desensitization and internalization [17]. Human
B cells express one CB2 transcript while mouse B cells
express three CB2 transcripts [18]. Furthermore, the het-
erogeneity of mouse splenic B lymphocytes may hinder
the molecular analysis of the mechanism of action of
SR144528 on B cell differentiation [19,20].
Although CB2 is more highly expressed in B cells than
in other immune cell subsets, the mechanism by which
CB2 regulates B cell function is unclear. Information on
the modulatory activity of CB2 ligand SR144528 in the
differentiation of B lineage plasma cells is also limited.
To explore the role of CB2 receptor signaling in the im-
munoglobulin production in plasma cell, we employed
the human B cell line SKW 6.4 to investigate the effects
of CB2 ligands on cytokine-induced IgM production.
This cell line has been shown to be capable of differenti-
ating into IgM-secreting cells once treated with human
IL-6 [21] and suitable for the analysis of immunomodu-
lator activities [19,22]. Meanwhile, this study also helps
us probe the possible therapeutic implication of use of
CB2 ligands for certain clinical conditions including
hyperimmunoglobulinia. The roles of immunoglobulin
relevant transcription factors including Bcl6, PAX5 and
XBP-1 as well as STAT in this regulation were also
discussed. To our knowledge, this is the first report
showing the modulation effects of CB2 antagonists on
IL-6-induced IgM secretion in the differentiated human
B cell.Methods
Reagents and cell culture
Recombinant human IL-6 was purchased from Gen-
Script (Piscataway, NJ). Cannabinoid CB2 inverse agonist
SR144528 and CB1 antagonist SR141716 were provided
by NIH-NIDA-NDSP program. AM630 (CB2 inverse
agonist) and HU308 (CB2 agonist) were purchased from
Cayman Chemical (Ann Arbor, MI). Human IgM ELISA
Kit (Immunology Consultants Laboratory, Inc., Portland,
OR) was used according to manufacturer’s recommenda-
tions. 3H-Thymidine (46.5 Ci/mmol) was purchased from
PerkinElmer (Boston, MA). TPA and LPS were from
Sigma-Aldrich (Saint Louis, MO).
The human SKW 6.4 cell line was obtained from
American Type Culture Collection. Cells were cultured
in RPMI-1640 medium with 10% heat-inactivated fetal
bovine serum (FBS), 2 mmol/L glutamine, and 100 U/mL
penicillin–streptomycin (Sigma-Aldrich) at 37°C with 5%
CO2. For the experiments, SKW 6.4 cells (5 × 10
4/ml)
were placed in 96-well flat-bottomed microtiter plates
(200 μl/well) and were incubated with or without IL-6,
SR144528 and the other agents for various times at 37°C.
CB2 ligands were prepared in dimethyl sulfoxide (DMSO)
stock solutions of 50 mM and diluted by medium before
application. For all the cell cultures with CB2 ligands, the
final concentrations of DMSO were always equal or less
than 0.05%. Control cells were also treated with an equiva-
lent amount of DMSO without the drugs.
Determination of IgM secretion
Supernatants of SKW 6.4 cell cultures were harvested by
centrifugation for the IgM enzyme-linked immunosorb-
ent assay (ELISA). The IgM levels were assayed by sand-
wich ELISA following the kit manufacturer’s instruction.
Briefly, each supernatant sample containing IgM was
added into the well of the microtiter plates that have
been coated with anti-human IgM antibodies. The plates
were incubated at room temperature for 1 hr. After
washing, anti-IgM antibody conjugated with horseradish
peroxidase was added to the well and the plates were
allowed to incubate for another 0.5 hr. After washing, cit-
rate buffer (pH 3.3) containing the chromogen-substrate
solution (3,3’5,5’-tetramethybenzidine and hydrogen per-
oxide) was added and incubated for 10 min in the dark.
The optical densities at 450 nm were measured and the
quantity of IgM in the test sample was interpolated from
the standard curve constructed from the standards
(human IgM calibrator) and corrected for sample dilution.
Cell proliferation assay (3H-thymidine incorporation)
Growth of SKW 6.4 cells was measured by the 3H-thy-
midine incorporation method [23]. The cells were cul-
tured in 96-well culture plates in RPMI-1640 medium
containing 10% FBS with or without drugs for 72 hours
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3H-thymidine during the last 8 hours of culture, harvested
onto glass fiber filter mats (Wallac) with an automatic cell
harvester. The radioactivity was determined by using a
TopCount NXT scintillation counter (PerkinElmer).
Real-time RT-PCR analysis
Total RNA was extracted with Trizol Reagent from Invi-
trogen (Invitrogen, Carlsbad, CA). The cDNA was syn-
thesized from 1.0 μg of total RNA with the random
hexamer primers and SuperScript RT III enzyme (Invi-
trogen), according to the manufacturer's protocol. SYBR
Green-based real-time PCR was performed with the ABI
7300 Real-Time PCR System (Applied Biosystems, Foster
City, CA). Data were normalized against the control of
GAPDH signals.
The sequences for PCR primers were:
BCL6 forward 5’-GATGAGATTGCCCTGCATTT-3’
and reverse 5’-TTCTTCCAGTTGCAGGCTTT-3’.
PAX-5 forward 5’-GACGACATGAAGGCCAATCT-3’
and reverse 5’-TACTGAGGGTGGCTGTAGGG-3’.
GAPDH forward 5’-GAAGGTGAAGGTCGGAGT-3’
and reverse 5’-GAAGATGGTGATGGGATTTC-3’.
SDS-PAGE and Western blotting
Western blotting was conducted as previously described
[24]. Briefly, cells were harvested, lysed with radioimmu-
noprecipitation assay buffer (Pierce) containing phos-
phatase and protease inhibitors (Halt Protease Inhibitor
Cocktail Kit; Pierce). Lysates were analyzed by SDS-PAGE
and transferred to a polyvinylidene fluoride membrane.
Following probing with specific primary antibodies plus
horseradish peroxidase-conjugated secondary antibody,
the protein bands were detected using SuperSignal West
Pico Chemiluminescent Substrate (Pierce).
Statistical analysis
Data values are expressed as mean ± S.D. Statistical dif-
ferences were determined by Student t test. Results were
considered significantly different for P < 0.05.
Results and discussion
IL-6 induces IgM secretion in a concentration-dependent
manner
Upon stimulation with IL-6, 12-O-tetradecanoylphorbol-
13-acetate (TPA) or lipopolysaccharide (LPS), B cells are
activated, rapidly proliferate and initiate differentiation
processes leading to increased antibody secretion, e.g.,
immunoglobulin M (IgM) [19,21,22,25,26]. To determine
which stimulator was most efficient for the present study,
we treated SKW 6.4 cells with rhIL-6 (50-1600 U/ml),
TPA (1-1000 nM) or LPS (1-5 μM) for 4 days. Among the
three stimulators, only IL-6 raised the IgM secretion
in a concentration-dependent manner, whereas TPA andLPS both could increase immunoglobulin production but
without clear concentration responses over these ranges
of concnetration (Figure 1A). We speculate that the differ-
ent responses among the three stimulators may have
resulted from their diverse downstream signal activation
[19,21,27]. For the well-controlled study below, we chose
to use IL-6 as the inducer of IgM secretion in SKW 6.4
cells.Inhibition of IL-6-triggered IgM production by CB2 inverse
agonists
CB2 is primarily expressed in B plasma cells [3]. To
determine CB2 gene expression in SKW 6.4 cells and
assure the action of CB2 ligands, we first measured CB2
expression level by using immunoblot assay. As shown
in Figure 1B, CB2 expression was detected in human
SKW 6.4 cells and the positive controls, human malig-
nancy plasma myeloma cells (MM1.S and U266).
SKW 6.4 cells were next treated with three CB2
ligands (agonist HU308 and inverse agonists AM630,
SR144528) in the presence or absence of IL-6 and IgM
levels in the culture supernatant were measured. Strik-
ingly, it was not the agonist, but the CB2 inverse
agonists that reduced IL-6-induced IgM secretion in a
concentration-dependent fashion (Figure 1C). The in-
hibitory effect of SR144528 was indicated by 100% and
160% decreases in IgM production at 5 μM and 10 μM,
respectively, relative to cells treated with IL-6 alone.
AM630 also showed inhibitory effects; whereas the ago-
nist HU308 failed to inhibit IL-6-induced IgM produc-
tion in the range of the tested concentrations (5-20 μM)
(Figure 1C).
To rule out the possibility that the modulating effects
of CB2 ligands on IgM production resulted from inhib-
ition of cell proliferation, we treated the SKW 6.4 cells
with various concentrations of the ligands for three days
in the presence of IL-6. As shown in Figure 1D, treat-
ment of SKW 6.4 cells with inverse agonists (AM630
below 5 μM, SR144528 below 10 μM) or agonist (HU308
below 20 μM) has no inhibitory effects on the growth of
SKW 6.4 cells, as determined by the 3H-thymidine incorp-
oration assay. These results indicate that the ligands may
affect IL-6 signal transduction and IgM production inde-
pendent of any effect on cell proliferation. In addition,
SKW 6.4 cell culture without IL-6 also expressed a basal
level of IgM. To see whether CB2 ligand SR144528 ex-
hibits any modulation of the spontaneous IgM secretion,
we treated SKW 6.4 cells with SR144528 only (0.1-10 μM)
in the absence of IL-6 for 4 days. Data shown in Figure 1E
revealed that exposure to SR144528 only slightly disturbed
the IgM autocrine production relative to control vehicle.
This suggests that SR144528 specifically influences IL-6-
induced IgM production.
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Figure 1 Effects of CB2 ligands on IL-6-induced IgM production in SKW6.4 cells. (A) IL-6, but not TPA or LPS, stimulated IgM secretion in a
concentration dependent manner. SKW 6.4 cells were incubated for 4 days with the indicated concentrations of IL-6 (white bar), TPA (grey bar) or
LPS (black bar). The secreted IgM was determined by ELISA. Background IgM secretion was 119 ng/ml and was subtracted from the IL-6-induced
secreted IgM shown. (B) Expression of CB2 receptor in SKW 6.4 and human B malignancy myeloma cells MM1.S and U266. (C) Modulation of
IL-6-induced IgM secretion by CB2 ligands. SKW 6.4 cells were incubated for 4 days with CB2 ligands (μM) plus IL-6 (100 U/ml in 0.04% DMSO).
The secreted IgM was determined by ELISA. Background IgM secretion was 176 ng/ml and was subtracted from the IL-6-induced secreted IgM
shown. Results were expressed as mean ± SD of three assays. (D) Effects of CB2 ligands on SKW6.4 cell proliferation. SKW 6.4 cells were incubated
for 4 days with CB2 ligands plus IL-6 (100 U/ml in 0.04% DMSO). Cell DNA synthesis was determined with 3H-Thymidine uptake assay. (E) SKW6.4
cells were exposed to IL-6 (100 U/ml), SR144528 (0.1-10 μM) or vehicle control (0.05% DMSO, v/v) for 4 days. The untreated wells were used as
control (Con). The secreted IgM was determined by ELISA. A representative experiment is shown. *P < 0.05 compared with IL-6 treatment alone.
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plasma cells upon IL-6 stimulation is interrupted by the
CB2 antagonist in SKW 6.4 cells. These effects are not
derived from inhibition of cell growth. Since CB2 can
positively regulate B cell immunity to respond to foreign
antigens resulting in the early production of IgM, and
the production of antigen-specific IgM is inhibited in
CB2(-/-) mice [28], our data then suggest that CB2 an-
tagonism may display effects on IgM production similar
to that seen in a CB2 gene deletion.
CB2 agonists reverse the inhibitory effect of SR144528 on
IL-6-induced IgM secretion
To confirm the CB2 receptor-mediated inhibitory effects
on IL-6-induced IgM production, we pretreated SKW
6.4 cells with CB2 specific agonist prior to exposure to
SR144528. We observed that pretreatment with CB2
specific agonist HU308 (5 μM) prior to treatment with
antagonist SR144528 could reverse the inhibitory effect
of SR144528 on IL-6-stimulated IgM secretion (P = 0.06,
Figure 2). Higher concentration of HU308 (10 μM) failed
to further reverse the effects of SR144528 (data not
shown). Treatment with HU308 without SR144528 at
concentrations used in this study had no significant
effects on IL-6-stimulated IgM secretion (Figure 2) and
cell viability (Figure 1D). Hence this inhibitory effect on
IgM production may be mediated, in part at least, by the
peripheral CB2 receptor.IL-6 (100U/ml)     +          
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NF-κB inhibition prevents Igκ gene expression and per-
turbs the assembly of IgM on cell surfaces, which marks
the differentiation of immature B cells [29]. IL-6 may
lead to NF-κB activation through its biological interplay
of phosphorylated STAT3 signal crosstalk with NF-κB
[30,31]. In this study, we found that a NF-κB specific
inhibitor Bay11-7085 markedly inhibited the stimulatory
effect of IL-6 on IgM secretion at the concentration of
0.01 μM (Figure 3A). Bay11-7085, at the concentration
of 0.01 μM, had no inhibitory effect on the cell viability
(data not shown). To study the effect of IL-6 on the
NF-κB pathway, we used a higher concentration of IL-6
(300 U/ml) to treat the cells for a shorter time (45 min)
and detected the IκBα (a cytoplasmic inhibitor protein
of NF-κB) degradation. Although Bay11-7085 could in-
hibit IL-6-induced IκBα degradation, SR144528 pre-
treatment failed to significantly reverse the degradation
(Figure 3B). This demonstrated that SR144528 and
Bay11-7085 may not work in the same pathway on IL-6-
induced IgM production in SKW 6.4 cells.
Interestingly, SR141716, a specific CB1 receptor antag-
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Figure 3 Modulation of STAT3, but not NF-κB and PI-3 K and ERK/MEK, is involved in the inhibition of IL-6-induced IgM secretion by
SR144528. (A) SKW 6.4 cells were pretreated with CB2 antagonist SR144528 (10 μM) or CB1 antagonist SR141716 (5 or 10 μM) or the indicated
inhibitors (Bay11-7085, 0.01 μM; U0126: 15 μM; LY294002, 15 μM) for 30 min, followed by IL-6 (100 U/ml) exposure for 4 days. IgM in the culture
supernatants was measured by ELISA. Background IgM secretion was 99 ng/ml and was subtracted from the IL-6-induced secreted IgM shown.
(B) SKW 6.4 cells were pretreated with SR144528 (SR) or Bay11-7085 (Bay) for 30 min, followed by IL-6 (300 U/ml) stimulation for another 45 min.
After harvest, the whole-cell lysates were subjected to Western blot analysis and detected with indicated antibodies. β-Actin served as loading
control. The numbers below the IκB-α and p-STAT3 (705) bands indicated the normalized ratios of the target band and their respective β-Actin.
(C-D) SKW 6.4 cells were treated with IL-6 in the absence or presence of SR144528 (SR) for 24, 48 or 96 hrs, respectively. Total cellular RNA was
extracted with Trizol Reagent and reverse transcribed into cDNA by using SuperScript RT III enzyme. SYBR Green-based real-time PCR for each
gene was performed and the results were normalized against the control of GAPDH signals. Final concentrations of DMSO in the tested wells
were equal or less than 0.05%.
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mRNA [3], the above results led us to assume that the
inhibition activity observed on plasma cells could be
mediated mainly through the CB2 receptor.
Since phosphatidylinositol 3-kinase (PI3K) and ERK/
MAPK are all involved in IL-6 signaling and have been
implicated as important mediators of B-cell activationand differentiation signals [31,32], we next asked whe-
ther they play roles in IL-6-induced IgM secretion in
SKW 6.4 cells. We found that PI3K inhibitor LY294002
and MEK/ERK inhibitor U0126 failed to inhibit the IL-6
effect on IgM production (Figure 3A). In our cellular
system, IL-6 had no significant activation effect on ERK
kinase (Figure 3B). These data suggest that activation of
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ciated with IgM secretion in SKW 6.4 cells. Our data are
consistent with a previous report, in which IL-6 was
shown to activate ERK, but the blockade of MEK/ERK
had only a minimal effect on IL-6–induced IgM secre-
tion in human BCWM.1 cells [33].
IL-6 is able to transduce intracellular signaling through
a receptor complex called IL-6R but the downstream
IL-6/PI3K and IL-6/ERK pathways have not yet been
sufficiently addressed. Unlike TPA, IL-6 has been de-
monstrated as inactive to stimulate ERK-2 in SKW6.4
cells, but IL-6 can activate ERKs in another human B
cell line, AF-10 [34]. We may therefore conclude from
our data and literature reports that ERK status plays in-
essential role in IL-6-induced IgM secretion in SKW6.4
cells.
Phosphorylation of STAT3 is critical for B cell dif-
ferentiation into immunoglobulin-secreting plasma cells
[35,36]. Down-regulation of STAT3 can reduce IgM
secretion [37]. As shown in Figure 3B, IL-6 strikingly
induced STAT3 phosphorylation after 30 min exposure,
whereas SR144528 pretreatment could moderately in-
hibit IL-6-raised STAT3 phosphorylation (Figure 3B). IκB
kinase inhibitor Bay11-7085 could block IL-6-mediated
STAT3 activation, supporting the existence of a link be-
tween NF-κB and STAT3 pathways in the context of IL-6
stimulation [30,31]. Pretreatment with SR144528, how-
ever, had no effect on IL-6-induced NF-κB activation,
ruling out the possibility that SR144528 may inhibit IgM
through the NF-κB pathway.
Besides the above kinases, several key regulatory pro-
teins in the B-cell transcriptional network have been
identified, with two coupled mutually repressive feed-
back loops among the three transcription factors: B-cell
lymphoma 6 (Bcl-6), B lymphocyte-induced maturation
protein 1(Blimp-1), and paired box 5 factor (Pax5) form-
ing the core of the network [38,39]. Pax5 negatively reg-
ulates a set of genes associated with antibody secretion
by plasma cells such as J chain, IgH and X-box binding
protein 1 (XBP-1). Thus overexpression of Pax5 leads to
increased cell proliferation and suppression of Ig synthe-
sis [38]. By RT-qPCR assay, we found that Pax5 and Bcl-6
mRNA levels were dramatically increased by SR144528
treatment in IL-6-treated SKW 6.4 cells (Figure 3C-D).
The time sequence showed that Pax5 was transacti-
vated before Bcl-6, suggesting the early transient upreg-
ulation of Pax5 by SR144528 initiated the inhibition of
IL-6 effect on IgM. Transactivation of Bcl-6 would be
expected to continue to suppress plasma cell differenti-
ation through negatively targeting the Blimp-1 gene,
thus impeding differentiation to secretion. Other lines
of evidence in the literature support our results. Bcl-
6-/- mice have elevated antibody response and increased
Ig-secreting cells [40]. In addition, decreased Blimp-1transcription and upregulation of Pax5 inhibit B-cell
differentiation into antibody-secreting plasma cells [38].
Conclusion
In summary, we found that CB2 inverse agonists inhib-
ited IL-6-induced immunoglobulin in human SKW 6.4
cells through regulation of STAT3 pathway and relevant
transcriptional factors including Bcl-6 and Pax5. Our
study corroborates the finding that cannabinoids exhibit
important regulation in the early humoral immune re-
sponse through CB2 specific expression in B cells. In-
terestingly, SR144528 had no effect on the constitutive
secretion of IgM but effectively diminished IL-6-induced
immunoglobulin production. By contrast, the CB2 recep-
tor agonist HU308 (5-20 μM) did not itself induce an
inhibitory effect; however, it reduced the inhibitory effect
of SR144528 on IL-6-induced IgM. The findings on the
regulatory function of the CB2 ligands in this study
differs from the one described by Eisenstein et al. [7] be-
cause our use of human cells requires IL-6 stimulation.
Whether CB2 inverse agonists negatively regulate patho-
logic globulin production (such as autoimmune Ab or
paraprotein in myeloma) warrants further study.
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